Table 1.
Characteristics of the study population and reactive hyperaemia–peripheral arterial tonometry.
| Variable | GROUP 1 (Active COVID-19) |
Group 2 (Past COVID-19) |
Overall COVID-19 (Groups 1 and 2) | Group 3 (Matched controls) |
P value (COVID-19 vs matched controls) |
|---|---|---|---|---|---|
| Baseline characteristics | |||||
| Age | 54 (18) | 59 (25) | 54.8 (15.4) | 53.9 (14.7) | 0.717 |
| Female sex | 9 (45.0%) | 27 (52.9%) | 36 (50.7%) | 36 (50.0%) | 0.933 |
| Body mass index | 28.1 (6.7) | 27.4 (7.5) | 28.4 (5.1) | 28.6 (5.2) | 0.803 |
| Hypertension | 6 (30.0%) | 19 (37.3%) | 25 (35.2%) | 25 (34.7%) | 0.951 |
| Dyslipidaemia | 5 (25.0%) | 16 (31.4%) | 21 (29.6%) | 29 (40.3%) | 0.180 |
| Diabetes | 3 (15.0%) | 10 (19.6%) | 13 (18.3%) | 10 (13.9%) | 0.472 |
| Current smoker | 0 (0%) | 2 (3.92%) | 2 (2.8%) | 2 (2.8%) | 0.989 |
| Coronary artery disease |
0 (0%) | 5 (9.80%) | 5 (7.0%) | 8 (11.1%) | 0.397 |
| Atrial fibrillation | 0 (0%) | 1 (1.96%) | 1 (1.4%) | 6 (8.3%) | 0.055 |
| Peripheral artery disease |
0 (0%) | 1 (1.96%) | 1 (1.4%) | 1 (1.4%) | 0.992 |
| Reactive hyperaemia–peripheral arterial tonometry | |||||
| Time from symptoms to EndoPAT (days) |
9.5 (6) | 101.5 (36) | NA | NA | <0.001 |
| Time from admission to EndoPAT (days) |
3 (3) | 92 (27) | NA | NA | <0.001 |
| LnRHI | 0.72 (0.26) | 0.53 (0.23) | 0.58 (0.25) | 0.79 (0.23) | <0.001 |
Values are presented as n (%) or n (interquartile range). LnRHI = natural logarithmic scaled reactive hyperemia index; NA = not applicable.